We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Zacks.com featured highlights: Lam Research, Xylem, Omega Healthcare Investors, Celanese and Electronic Arts
Read MoreHide Full Article
For Immediate Release
Chicago, IL – October 24, 2017 - Stocks in this week’s article include: Lam Research Corporation (LRCX - Free Report) , Xylem Inc. (XYL - Free Report) , Omega Healthcare Investors, Inc. (OHI - Free Report) , Celanese Corporation (CE - Free Report) and Electronic Arts Inc. (EA - Free Report)
Screen of the Week by Zacks Investment Research:
5 Best Stocks to Buy with Impressive Sales Growth to Buy Right Now
With Q3 earnings season in full swing, one must be looking to pick stocks based on their quarterly earnings as a company’s stock price is typically sensitive to its earnings momentum. But overlooking sales growth is not prudent. Earnings are quite vulnerable in the sense that books can be easily manipulated and the numbers inflated. That’s why sales should always be considered.
Accomplishing sales growth is extremely challenging in today’s multifaceted and fast-changing business environment. So, the companies have stepped up marketing initiatives over digital platforms and have become more professional about sales management to drive their top line.
Also, sales growth is an important metric for any company as it is a vital part of growth projections and instrumental in strategic decision making. Unsurprisingly, sales growth gets more attention from investors in the investment process, as a healthy sales growth rate is usually a positive investment indicator.
However, sales growth in isolation doesn’t reveal too much about a company’s future performance. Though it provides investors an insight into product demand and pricing power, a huge sales number does not necessarily translate into profits.
Therefore, consideration of a company’s cash position along with its sales number can be a more dependable strategy. Substantial cash in hand and a steady cash flow give a company more flexibility with respect to business decisions and potential investments. Most importantly, an adequate cash position suggests that revenues are being channelized in the right direction.
Disclosure: Officers, directors and/or employees of Zacks Investment Research may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material. An affiliated investment advisory firm may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material.
About Screen of the Week
Zacks.com created the first and best screening system on the web earning the distinction as the "#1 site for screening stocks" by Money Magazine. But powerful screening tools is just the start. That is why Zacks created the Screen of the Week to highlight profitable stock picking strategies that investors can actively use.
Strong Stocks that Should Be in the News
Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has more than doubled the market from 1988 through 2016. Its average gain has been a stellar +25% per year. See these high-potential stocks free >>.
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Contact: Jim Giaquinto Company: Zacks.com Phone: 312-265-9268 Email: pr@zacks.com
Zacks.com provides investment resources and informs you of these resources, which you may choose to use in making your own investment decisions. Zacks is providing information on this resource to you subject to the Zacks "Terms and Conditions of Service" disclaimer. www.zacks.com/disclaimer.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performancefor information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Zacks.com featured highlights: Lam Research, Xylem, Omega Healthcare Investors, Celanese and Electronic Arts
For Immediate Release
Chicago, IL – October 24, 2017 - Stocks in this week’s article include: Lam Research Corporation (LRCX - Free Report) , Xylem Inc. (XYL - Free Report) , Omega Healthcare Investors, Inc. (OHI - Free Report) , Celanese Corporation (CE - Free Report) and Electronic Arts Inc. (EA - Free Report)
Screen of the Week by Zacks Investment Research:
5 Best Stocks to Buy with Impressive Sales Growth to Buy Right Now
With Q3 earnings season in full swing, one must be looking to pick stocks based on their quarterly earnings as a company’s stock price is typically sensitive to its earnings momentum. But overlooking sales growth is not prudent. Earnings are quite vulnerable in the sense that books can be easily manipulated and the numbers inflated. That’s why sales should always be considered.
Accomplishing sales growth is extremely challenging in today’s multifaceted and fast-changing business environment. So, the companies have stepped up marketing initiatives over digital platforms and have become more professional about sales management to drive their top line.
Also, sales growth is an important metric for any company as it is a vital part of growth projections and instrumental in strategic decision making. Unsurprisingly, sales growth gets more attention from investors in the investment process, as a healthy sales growth rate is usually a positive investment indicator.
However, sales growth in isolation doesn’t reveal too much about a company’s future performance. Though it provides investors an insight into product demand and pricing power, a huge sales number does not necessarily translate into profits.
Therefore, consideration of a company’s cash position along with its sales number can be a more dependable strategy. Substantial cash in hand and a steady cash flow give a company more flexibility with respect to business decisions and potential investments. Most importantly, an adequate cash position suggests that revenues are being channelized in the right direction.
For the rest of this Screen of the Week article please visit Zacks.com at: https://www.zacks.com/stock/news/279690/5-best-stocks-with-impressive-sales-growth-to-buy-right-now
Disclosure: Officers, directors and/or employees of Zacks Investment Research may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material. An affiliated investment advisory firm may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material.
About Screen of the Week
Zacks.com created the first and best screening system on the web earning the distinction as the "#1 site for screening stocks" by Money Magazine. But powerful screening tools is just the start. That is why Zacks created the Screen of the Week to highlight profitable stock picking strategies that investors can actively use.
Strong Stocks that Should Be in the News
Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has more than doubled the market from 1988 through 2016. Its average gain has been a stellar +25% per year. See these high-potential stocks free >>.
Follow us on Twitter: http://twitter.com/zacksresearch
Join us on Facebook: http://www.facebook.com/ZacksInvestmentResearch
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Contact: Jim Giaquinto
Company: Zacks.com
Phone: 312-265-9268
Email: pr@zacks.com
Visit: www.Zacks.com
Zacks.com provides investment resources and informs you of these resources, which you may choose to use in making your own investment decisions. Zacks is providing information on this resource to you subject to the Zacks "Terms and Conditions of Service" disclaimer. www.zacks.com/disclaimer.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performancefor information about the performance numbers displayed in this press release.